Wed, Jul 30, 2014, 8:38 AM EDT - U.S. Markets open in 52 mins.

Recent

% | $
Click the to save as a favorite.

Mylan, Inc. Message Board

  • no need to exercise a poison pill, if the merger is not hostile.

    This topic is deleted.
    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • when mylan was trading at ridiculous low price mgt
      became extremely nervous.
      they adopted the poison pill because they knew true value
      of the company and they were in danger.

      insiders control very little of the stock they are ripe for a
      a takeover could be pfizer.pfizer is not to happy about
      mylans generic version of procardia xl.lilly has close ties
      with mylan could happen soon.the poison pill will make sure
      shareholders are treated fairly. K2B1

      • 2 Replies to King2Bishop1
      • mylan is headed for 15 to 16 k2b1.what the hell does that
        stand for anyways?
        they will get plenty of competition on zantac profit margins
        will erode.stock always goes down anyways.
        you can buy it alot cheater.
        besides its too dam expensive right now.
        you dont know what your talking about.

      • I've been seeing rumers being spread in this message column about all sorts of companies that might be targeting Mylan and at prices like $32 etc.

        It is common knowledge that companies like Bayer and Hoechst have been looking at companies and Mylan might fit the bill for such a company.... not Pfizer or Merk. In any event, the insiders at Mylan picked up stock last year and set up the poison pill becasue they knew that they were developing a new stradegy that was going to make the company attractive. Earnings will most definitely climb from here on out and the stock is going to go up

 
MYL
50.40-0.13(-0.26%)Jul 29 3:59 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.